O paciente deve retornar para avaliação clínica ainda no primeiro mês pós-ICP para
avaliação de queixas cardíacas e adesão ao tratamento. Durante o período de 3 a 6
meses da ICP, deve-se monitorar o aparecimento de angina ou de sintomas
equivalentes que possam significar reestenose. Nesses pacientes deve ser realizada
nova cineangiocoronariografia sem necessidade de teste não invasivo. Porém, em
razão da grande quantidade de pacientes com reestenose assintomática (cerca de
25%), recomenda-se realizar um teste isquêmico não invasivo localizatório (cintilografia
miocárdica, ecoestresse) de 6 meses a 1 ano do procedimento.
BIBLIOGRAFIA
Abizad A, Costa JR. New drug-eluting stents: an overview on biodegradable and
polymer-free next-generation stents systems. Circ Cardiovasc Interv. 2010;3:384-93
Armstrong PW, Gershlick A, Goldstein P, Wilcox R, Danays T, Bluhmki E et al. The
strategic reperfusion early after myocardial infarction (STREAM) study. Am Heart J.
2010;160(1):30-5.
Bavry AA, Kumbhani DJ, Rassi AN, Bhatt, DL, Askari AT. Benefit of early invasive
therapy in acute coronary syndromes: a meta-analysis of contemporary randomized
clinical trials. J Am Coll Cardiol. 2006; 48:1319-25.
Boden WE, O’Rourke RA, Teo KK, Weintraub WS. COURAGE Trial Research Group.
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J
Med. 2007;356:1503-16.
Cantor WJ, Fittchet D, Borgundvaag B, Ducas J, Heffrnan M, Cohen EA. for the
TRANSFER-AMI investigators. Routine early angioplasty after fibrinolysis for acute
myocardial infarction. N Engl J Med. 2009;360(26):2705-18.
Colombo A, Stankovic G, Moses JW. Selection of coronary stents. J Am Coll Cardiol.
2002;40:1021-33.
Costa RA, Lansky AJ, Abizaid A, Müelller R, Tsuchiya Y, Mori K et al. Angiographic
results of the first human experience with the biolimus A9 drug-eluting stent for de
novo coronary lesions. Am J Cardiol. 2006;98(4):443-6.
Dalby M, Bouzamondo A, Lechat P, Montalescat G. Transfer for primary angioplasty
versus immediate thrombolysis in acute myocardial infarction: a meta-analysis.
Circulation. 2003;108:1809-14.
Eisenstein EL, Leon MB, Kandzari DE, Mauri, L, Edwards R, Kong, DF et al. Long-term
clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the
cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial. JACC
Cardiovasc Interv. 2009;2(12):1199-1207.
Ellis SG, Tendera M, de Belder MA, van Boven AJ, Wichinsky P, Janssens L et al. for